MA
MARI.VI Marinomed Biotech AG
- Market cap
- EUR 8.00M
- P/E
- 0.4x
- P/B
- 597.26x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MARI.VI undervalued?
Graham numberThe Graham number of Marinomed Biotech AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Marinomed Biotech AG fundamental analysis
6 of 22 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 1/1
Return on assets (257.1%) is above the industry median (-19.8%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (195.9%) is above the industry median (3.8%).
Revenue Growth 0/2
Revenue shrank 11.9% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 37.4x against interest expense, well covered.
PE vs Market 1/1
PE (0.4x) is below the market median (18.5x).
PE vs Industry 1/1
PE (0.4x) is below the industry median (18.6x).
PBV 0/1
Price to book (597.3x) is above the industry median (3.1x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 236.5, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Marinomed Biotech AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Marinomed Biotech AG
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation developmen…
Full company profileMarinomed Biotech AG financial statements
Marinomed Biotech AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.61M | 4.81M | 4.67M | 6.14M | 8.12M | 11.6M | 11.3M | 9.18M | 4.75M | 7.70M |
| Gross Profit | 176K | 651K | -165K | -512K | -642K | 1.42M | 2.14M | 1.14M | -4.27M | 2.00M |
| Operating Income | -1.53M | -1.64M | -5.14M | -6.21M | -6.96M | -4.14M | -5.75M | -5.13M | -7.02M | 18.7M |
| EBITDA | -1.34M | -1.22M | -10.4M | -6.22M | -4.86M | -3.58M | -3.21M | -3.62M | -7.18M | 19.0M |
| Net Income | -1.97M | -2.38M | -12.1M | -7.22M | -6.01M | -5.89M | -6.40M | -6.79M | -15.4M | 15.3M |
| EPS | -1.27 | -1.53 | -7.79 | -5.09 | -4.09 | -3.99 | -4.27 | -4.48 | -8.67 | 8.32 |
| Balance Sheet | ||||||||||
| Total Assets | 4.92M | 9.33M | 5.26M | 19.5M | 23.5M | 21.3M | 22.3M | 14.6M | 8.18M | 5.95M |
| Total Liabilities | 7.57M | 14.4M | 21.5M | 8.64M | 18.1M | 21.1M | 26.4M | 24.7M | 34.1M | 12.8M |
| Shareholders' Equity | -2.65M | -5.03M | -16.3M | 10.9M | 5.36M | 191K | -4.16M | -10.1M | -26.2M | -9.80M |
| Cash & Short-term Investments | 2.01M | 6.03M | 1.72M | 12.0M | 9.21M | 5.80M | 8.18M | 2.59M | 1.71M | 1.00M |
| Total Debt | 5.93M | 10.8M | 10.6M | 4.64M | 12.8M | 15.8M | 22.6M | 21.8M | 29.5M | 11.6M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.53M | -2.18M | -4.32M | -7.64M | -6.88M | -4.87M | -5.20M | -4.53M | -2.40M | -1.10M |
| Capital Expenditure | 113K | 154K | 229K | 2.34M | 3.96M | 919K | 228K | 129K | 0.00 | 0.00 |
| Free Cash Flow | -2.64M | -2.34M | -4.54M | -9.98M | -10.8M | -5.79M | -5.43M | -4.66M | -2.40M | -1.10M |
| Ratios | ||||||||||
| ROE | - | - | - | -66.4% | -112.2% | -3,078.0% | - | - | - | - |
| ROA | -40.1% | -25.5% | -229.8% | -37.0% | -25.6% | -27.6% | -28.7% | -46.5% | -188.4% | 257.1% |
| Net Profit Margin | -75.7% | -49.4% | -259.2% | -117.4% | -74.0% | -50.7% | -56.7% | -74.0% | -324.8% | 198.7% |
| Debt to Equity | - | - | - | 0.43x | 2.39x | 82.54x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Marinomed Biotech AG dividends
Marinomed Biotech AG has not paid dividends in the last 10 fiscal years.
Who owns Marinomed Biotech AG
- Insiders 23.83%
- Institutions 14.81%
- Public & others 61.36%
- Shares outstanding 2.00M
- Free float 1.37M
Marinomed Biotech AG company profile
- Company name
- Marinomed Biotech AG
- Ticker
- MARI.VI
- ISIN
- ATMARINOMED6
- Exchange
- Vienna Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- Hovengasse 25, Korneuburg, Austria, 2100
- Phone
- 43 2262 90300
- Website
- marinomed.com
About Marinomed Biotech AG
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Marinomed Biotech AG management
4- Mr. Andreas Grassauer Ph.D.Co-Founder, Chairman of Management Board & CEO · born 1969
- Ms. Eva Prieschl-Grassauer Ph.D.Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer · born 1968
- Ms. Gabriele RamAuthorized Signatory, Head of Finance & Member of Management Board
- Ms. Stephanie KniepHead of Investor Relations